AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The country's health agency said there was “insufficient data” on the shot's effectiveness in people over the age of 65.

Germany Moves To Exclude Seniors From AstraZeneca's Covid-19 Vaccine

The public tete-a-tete between AZN and the EU could result in the EU restricting supply of AZN's COVID-19 vaccine outside the EU. The vaccination rollout has been slow in the U.S. as well. PFE or MRNA could capitalize on any AZN supply constraints.

AstraZeneca's Supply Issues Could Change The COVID-19 Game Board

The European Union has accused AstraZeneca of backtracking on its commitment to deliver 80 million Covid-19 vaccine doses by the end of March.

EU-AstraZeneca Row Escalates As Belgian Regulators Launch Probe Into Vaccine Production Site

The COVID-19 vaccine developed by AstraZeneca and the University of Oxford shouldn't be given to people over age 65, Germany's main public health agency said Thursday, multiple media outlets reported. "There are currently insufficient data available to assess the vaccine efficacy from 65 years of age," said the Vaccine Commission at the Robert Koch Institute, Reuters reported. For that reason, the health body recommended that the vaccine only be given to people ages 18 to 64, according to Reuters and the Financial Times.

AstraZeneca's COVID-19 shot shouldn't be given to people over 65, Germany's vaccine committee reportedly says

French biotech Valneva will start manufacturing the first 60 million doses of its experimental shot in Scotland within days.

As EU battles AstraZeneca shortages, U.K. races ahead with manufacture of new COVID vaccine

Germany's vaccine committee recommended only using the AstraZeneca/University of Oxford coronavirus vaccine on those between 18 and 64 years of age, according to wire service reports. AstraZeneca CEO Pascal Soirot had said that was a possibility, which he said was due to lack of data compared to other vaccine manufacturers.

Germany recommends only using AstraZeneca vaccine on under-65s

Portnoy Law: Lawsuit Filed On Behalf of AstraZeneca PLC Investors

The EU has told drugmaker AstraZeneca divert supplies of its coronavirus vaccine from the U.K. to mainland Europe, as a battle rages over supplies to the bloc.

EU suggests AstraZeneca diverts supplies of Covid-19 vaccine from UK, as battle over supplies brews

SAN FRANCISCO, Jan. 28, 2021 /PRNewswire/ -- Hagens Berman urges AstraZeneca PLC (NASDAQ: AZN) investors to submit their losses now. A securities fraud lawsuit has been filed and certain investors may have valuable claims. Class Period: May 21, 2020 – Nov. 20, 2020 Lead Plaintiff...

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Invites AstraZeneca (AZN) Investors to Contact Firm, Securities Fraud Case Related to Potential COVID-19 Treatment Filed

NEW YORK--(BUSINESS WIRE)-- #AstraZeneca--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, announces that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased AstraZeneca PLC (NASDAQ: AZN) American Depository Shares (“ADSs”) between May 21, 2020 and November 20, 2020 (the “Class Period”). Investors have until March 29, 2021 to apply to the Court to be appointed as lead plaintif

ASTRAZENECA ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AstraZeneca PLC and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $AZN #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AstraZeneca PLC (AZN) on Behalf of Investors

The EU's health commissioner Stella Kyriakides urged AstraZeneca to supply the bloc with more doses of its vaccine from U.K. plants amid a row over shortages.

EU demands access to U.K.-made AstraZeneca vaccine shots as row over shortages intensifies

NEW YORK--(BUSINESS WIRE)--Labaton Sucharow, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for AstraZeneca investors under the federal securities laws. According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to d

AZN EQUITY ALERT: Labaton Sucharow Announces Filing of Securities Class Action Lawsuit Against AstraZeneca PLC – NASDAQ: AZN

Production of the Oxford-AstraZeneca COVID-19 vaccine has been suspended after one of its largest plants received a "suspicious package" and had to evacuate workers. A spokesman for the Wockhardt UK plant in Wrexham, Wales, said the site received the package on Wednesday morning.

Production of AstraZeneca's COVID-19 vaccine has been suspended after a 'suspicious package' was sent to one of its largest plants

The EU accused the company of abandoning its commitments to make a profit elsewhere.

AstraZeneca Hits Back At EU Accusation It's Backtracking On Its Covid-19 Vaccine Contract

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of AstraZeneca PLC (NASDAQ: AZN) between May 21, 2020 and November 20, 2020, inclusive (the "Class Period"). The lawsuit seeks to recover damages for AstraZeneca investors under the federal securities laws. To join the AstraZeneca class action, go to http://www.rosenlegal.com/cases-register-2027.html or call Phillip Kim, Esq. toll

AZN EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against AstraZeneca PLC – AZN

Here's what you need to know to navigate the markets today.

AstraZeneca Denies Pulling Out of Meeting With EU on Vaccine Deliveries

AstraZeneca is pushing back strongly against criticism from EU officials over delayed deliveries of its Covid-19 vaccine.

EU vaccine delivery dates weren't guaranteed, says AstraZeneca CEO

AstraZeneca has defended its delayed rollout of the coronavirus vaccine to the EU, but said the bloc had ordered later than others.

AstraZeneca defends slow supplies to the EU, but says it ordered 3 months later than the U.K.

NEW YORK--(BUSINESS WIRE)-- #AZNADSs--The suit alleges defendants issued false statements re: AstraZeneca business and prospects, resulting in its stock trading at inflated prices.

Robbins Geller Rudman & Dowd LLP Files Class Action Suit Against AstraZeneca plc

EU officials said that pharmaceutical companies producing Covid vaccines would be required to register in advance exports of doses to third countries.

Tensions Rise in Europe on AstraZeneca Vaccine Woes

Reports in German media outlets that the Oxford-AstraZeneca COVID-19 vaccine is less effective in older people appear to be unfounded, the German government said Tuesday. German newspapers Handelsblatt and Bild reported Tuesday that the vaccine worked significantly less well in those over 65, and that this could affect whether the vaccine was authorized for this age group in EU countries. Bild had the efficacy figure at "less than 10%," Handelsblatt at 8%.

Reports that AstraZeneca's vaccine is less effective in older people appear to be based on botched statistics, the German government says

The EU is demanding AstraZeneca honor its agreement to deliver millions of doses of its vaccine as the company pushes back on German media claiming it has an efficacy of 8% among older people.

AstraZeneca Battles Supply Chain Issues, Denies Claims Its Covid-19 Vaccine Is Largely Ineffective In Seniors

Pfizer

The European Union is calling out vaccine makers AstraZeneca and Pfizer over delivery delays that could slow its recovery from the pandemic. Officials are even threatening to introduce export controls on doses produced in the bloc as anger mounts.

Pfizer and AstraZeneca take heat as vaccine delays threaten Europe's recovery

British-Swedish vaccine maker AstraZeneca is fighting battles on several fronts this week.

News for AstraZeneca Stock (AZN)